[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,201,816
  • Shares Outstanding, K 308,950
  • Annual Sales, $ 348,970 K
  • Annual Income, $ 5,860 K
  • EBIT $ 23 M
  • EBITDA $ 36 M
  • 60-Month Beta 1.12
  • Price/Sales 3.63
  • Price/Cash Flow 64.00
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 88.03% (+4.48%)
  • Historical Volatility 64.84%
  • IV Percentile 12%
  • IV Rank 8.89%
  • IV High 500.78% on 10/09/25
  • IV Low 47.76% on 12/17/25
  • Expected Move (DTE 7) 0.09 (2.19%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 3,376
  • Volume Avg (30-Day) 5,633
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 93,939
  • Open Int (30-Day) 83,973
  • Expected Range 3.81 to 3.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 2
  • High Estimate $0.03
  • Low Estimate $-0.05
  • Prior Year $0.03
  • Growth Rate Est. (year over year) -133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.69 +5.42%
on 08/06/26
4.41 -11.71%
on 07/07/26
-0.38 (-8.90%)
since 07/06/26
3-Month
2.93 +32.76%
on 05/19/26
4.55 -14.51%
on 07/06/26
+0.33 (+9.27%)
since 05/06/26
52-Week
2.23 +74.44%
on 03/27/26
6.51 -40.25%
on 01/08/26
+0.43 (+12.27%)
since 08/06/25

Most Recent Stories

More News
MannKind: Q2 Earnings Snapshot

MannKind: Q2 Earnings Snapshot

MNKD : 3.89 (-5.12%)
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment...

MNKD : 3.89 (-5.12%)
MannKind's Pipeline Enthusiasm Meets a DCF Model That Suggests Fifteen Dollars Lower

Barchart Research What to Expect from MNKD Earnings MNKD Generated August 4, 2026 Current Price $3.96 EPS Estimate $$-0.02 Consensus Rating Moderate Buy Average Move 7.97% MannKind's Pipeline Enthusiasm...

MNKD : 3.89 (-5.12%)
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough ~450 total inhalations administered...

MNKD : 3.89 (-5.12%)
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced that the Company will report second quarter 2026 financial results...

MNKD : 3.89 (-5.12%)
MannKind Announces $50 Million Private Placement

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 3.89 (-5.12%)
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

Transformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital setting Delivers IV-equivalent diuretic...

MNKD : 3.89 (-5.12%)
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE...

MNKD : 3.89 (-5.12%)
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize...

MNKD : 3.89 (-5.12%)
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical...

MNKD : 3.89 (-5.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder...

See More

Key Turning Points

3rd Resistance Point 4.22
2nd Resistance Point 4.08
1st Resistance Point 3.98
Last Price 3.89
1st Support Level 3.74
2nd Support Level 3.60
3rd Support Level 3.50

See More

52-Week High 6.51
Fibonacci 61.8% 4.88
Fibonacci 50% 4.37
Last Price 3.89
Fibonacci 38.2% 3.86
52-Week Low 2.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.